{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:04Z","timestamp":1793381044498,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.parkreldis.2014.09.034","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T22:56:40Z","timestamp":1416524200000},"page":"111-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia"],"prefix":"10.1016","volume":"21","author":[{"given":"Joaquim J.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savary","family":"Om","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a01","key":"10.1016\/j.parkreldis.2014.09.034_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","article-title":"Epidemiology, clinical presentation, and diagnosis of cervical dystonia","volume":"26","author":"Stacy","year":"2008","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.parkreldis.2014.09.034_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur J Neurol"},{"issue":"19","key":"10.1016\/j.parkreldis.2014.09.034_bib3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2014.09.034_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.parkreldis.2014.09.034_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","article-title":"Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review","volume":"22","author":"Colosimo","year":"2012","journal-title":"Neurotox Res"},{"issue":"2","key":"10.1016\/j.parkreldis.2014.09.034_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","volume":"5","author":"Ramirez-Castaneda","year":"2013","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.parkreldis.2014.09.034_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","article-title":"Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?","volume":"32","author":"Lange","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.parkreldis.2014.09.034_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/00207454.2012.668725","article-title":"Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxina (Dysport)","volume":"122","author":"Coleman","year":"2012","journal-title":"Int J Neurosci"},{"issue":"3","key":"10.1016\/j.parkreldis.2014.09.034_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2014.09.034_bib10","first-page":"265","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group","volume":"246","author":"Kessler","year":"1999","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2014.09.034_bib11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2014.09.034_bib12","first-page":"225","article-title":"Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia","volume":"27","author":"Ferreira","year":"2012","journal-title":"Funct Neurol"},{"issue":"2","key":"10.1016\/j.parkreldis.2014.09.034_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pds.1471","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"17","author":"ISPE","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.parkreldis.2014.09.034_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J\u00a0Neural Transm"},{"issue":"9","key":"10.1016\/j.parkreldis.2014.09.034_bib15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2014.09.034_bib16","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.parkreldis.2011.06.015","article-title":"Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses","volume":"17","author":"Bhidayasiri","year":"2011","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.parkreldis.2014.09.034_bib17","series-title":"Dystonia \u2013 the many facet","article-title":"Dystonias of the neck: clinico-radiologic correlations","author":"Reichel","year":"2012"},{"key":"10.1016\/j.parkreldis.2014.09.034_bib18","doi-asserted-by":"crossref","first-page":"e000881","DOI":"10.1136\/bmjopen-2012-000881","article-title":"Factors influencing response to botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study","volume":"2","author":"Misra","year":"2012","journal-title":"BMJ Open"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802014004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:22:17Z","timestamp":1589289737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802014004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1353802014004234"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.034","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}